News from Thursday, March 28, 2024
Articles
With PCORI’s Support, ADVANCE Clinical Research Network Expands
(3/28, David Raths, Healthcare Innovation) reports “...The new PCORI funding will build on the framework that ADVANCE has established and further enhance its national footprint by: Increasing regional representation of the Pacific Northwest in the ADVANCE network; Adding hospital-based clinical data to the data warehouse for the first time, enabling more complete longitudinal data for ADVANCE patients (both inpatient and outpatient); Integrating additional sources of data to inform new research, including genomics, tissue, and biospecimens; and Bringing additional expertise in clinical trials to the ADVANCE team.” Full
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
(3/27, Francesca Bruce, Pink Sheet) reports “...In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.” Subscription Required
Press Releases
Vamorolone Not Recommended by NICE
(3/28, Duchenne UK Press Release) “Today, the National Institute for Health and Care Excellence published its decision to not approve a treatment for Duchenne muscular dystrophy (DMD) called vamorolone. Vamorolone, also known by the brand name Agamree, was meant to be an alternative to conventional steroids such as prednisone or deflazacort.” Full
Journals
Comparative Effectiveness of Adjuvant Therapy on Survival in Patients With Metastatic Colorectal Cancer
Chih-Chien Wu, et al.
April 2024, Anticancer Research
Reports
Patient-Centered Outcomes Research Institute: Review of the Audit of the FY 2023 Financial Statements
March 28, 2024
Events
Reminder: 2024 Science of Patient Engagement Symposium
May 8 - 9, 2024
National Press Club
Washington, DC